Skip to main content
Immuno-Biological Laboratories Co., Ltd. logo

Immuno-Biological Laboratories Co., Ltd. — Investor Relations & Filings

Ticker · 4570 ISIN · JP3921300004 T Manufacturing
Open in API
Filings indexed 65 across all filing types
Latest filing 2026-05-29 Investor Presentation
Country JP Japan
Listing T 4570

About Immuno-Biological Laboratories Co., Ltd.

https://www.ibl-japan.co.jp/en/

Immuno-Biological Laboratories (IBL) is a research and development-focused company that develops, manufactures, and supplies immunological research reagents and in-vitro diagnostic products for the global life sciences community. The company's core offerings include a comprehensive range of ELISA kits, antibodies, and cell culture-related products. IBL specializes in several key research areas, including aging, neurodegenerative disorders, kidney diseases, inflammatory diseases, and glucose/lipid metabolism. A notable proprietary technology is the LipoSEARCH® lipoprotein analyzing system, which uses patented GP-HPLC methods. The company also provides customized services to support specific research requirements.

Recent filings

Filing Released Lang Actions
事業計画及び成長可能性に関する説明
Investor Presentation Classification · 96% confidence The document is a slide-like presentation titled “事業計画及び成長可能性に関する説明” (Business Plan and Growth Prospects) with sections such as company overview, business segments, mid-term management plan & risks, growth strategy, and numeric targets. It is structured as an investor-facing presentation rather than a formal financial report (e.g., 10-K, quarterly report) or a brief announcement. It contains strategic content, charts, tables of forecasts, and imagery typical of an Investor Presentation. Therefore, it should be classified as an Investor Presentation.
2026-05-29 Japanese
2026年３月期（第44期）決算説明資料
Investor Presentation Classification · 95% confidence The document is titled “決算説明資料” (Earnings Explanation Materials) and presents detailed slide-format financial results for the 2026 fiscal year and a business plan for the following year. It includes tables, charts, and commentary on sales, segment performance, balance sheet, cash flows, forecasts, and strategic initiatives. It is a presentation aimed at investors rather than a concise earnings release or full statutory filing (e.g., 10-K) and not simply an announcement of a report publication. Therefore, it best fits the «Investor Presentation (IP)» category.
2026-05-28 Japanese
確認書
Report Publication Announcement Classification · 100% confidence The document is a 'Confirmation Letter' (Kakunin-sho) filed under the Financial Instruments and Exchange Act, specifically confirming the accuracy of the contents of a Semi-Annual Report (Hankishokokusho) for the period ending September 30, 2025. Since this is a regulatory filing required by law to accompany financial reports and does not fit into the specific categories of financial statements or earnings releases, it is classified as a Regulatory Filing (RNS).
2025-11-14 Japanese
半期報告書－第44期(2025/04/01－2026/03/31)
Interim / Quarterly Report Classification · 100% confidence The document is a '半期報告書' (Semi-Annual Report) filed by '株式会社免疫生物研究所' (Immuno-Biological Laboratories Co., Ltd.) for the period ending September 30, 2025. It contains detailed financial statements, including the balance sheet and income statement, and is prepared in accordance with Japanese GAAP. As it is a comprehensive financial report for a period shorter than a full fiscal year containing substantive financial data, it is classified as an Interim/Quarterly Report. H1 2026
2025-11-14 Japanese
臨時報告書
AGM Information Classification · 100% confidence The document is titled '臨時報告書' (Extraordinary Report) and explicitly states in Section 1 that it is being submitted because the resolutions from the '定時株主総会' (Annual General Meeting - AGM) held on June 26, 2025, have been finalized, citing relevant Japanese financial regulations (FSA Order Article 19, Paragraph 2, Item 9-2). Section 2 details the resolutions, specifically the election of five directors, and provides the vote counts (For, Against, Abstain) for each candidate. This content directly relates to the official results of a shareholder vote following an AGM. Therefore, the most appropriate classification is Declaration of Voting Results & Voting Rights Announcements (DVA).
2025-06-27 Japanese
内部統制報告書－第43期(2024/04/01－2025/03/31)
Governance Information Classification · 100% confidence The document contains a header section explicitly stating the filing type as "内部統制報告書" (Internal Control Report) and references the legal basis as "金融商品取引法第24条の４の４第１項" (Article 24-4-4, Paragraph 1 of the Financial Instruments and Exchange Act). The content discusses the framework, scope, criteria, and conclusion regarding the assessment of internal controls over financial reporting ("財務報告に係る内部統制"). This directly corresponds to the requirements for an internal control report, which is typically filed alongside the Annual Report (10-K) but is a distinct regulatory document focusing solely on internal controls. Given the specific nature of the content (Internal Control Report) and the lack of a direct match in the provided codes, the closest conceptual fit among the options that deals with formal, comprehensive reporting and regulatory compliance is the Annual Report (10-K), although 'AR' (Audit Report/Information) is also a possibility if the document is interpreted as a standalone assurance report. However, since this is a management assertion on internal controls, and not a standard Audit Report, and it is not the full 10-K, it is a specialized regulatory filing. In the context of US SEC filings, the Internal Control Report is a required component of the 10-K. Since there is no specific code for an 'Internal Control Report', and it is a formal, comprehensive report on financial integrity, it is most closely related to the comprehensive annual reporting structure. Given the options, and recognizing this is a formal regulatory filing about financial integrity, I will classify it as 'AR' (Audit Report / Information) as it relates to assurance/verification of financial processes, or 'RNS' as a fallback. Given the detailed nature and formal structure, it is more substantial than a simple RNS. Since 'AR' covers 'applied accounting principles, and results of internal or regulatory stress tests', this fits the theme of internal control assessment better than other options. However, if we strictly adhere to the definitions, this is a management assertion, not an external audit report. Therefore, the most appropriate fallback for a formal, non-standard regulatory document is RNS, or if we must choose a financial reporting category, 10-K is too broad if it's just this section. Let's re-evaluate: The document is a formal Japanese regulatory filing (Internal Control Report). Since there is no specific code for this, and it is a formal report, I will use the fallback 'RNS' (General regulatory announcements/miscellaneous filings).
2025-06-27 Japanese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.